The association between ß-glucocerebrosidase mutations and parkinsonism

Current Neurology and Neuroscience Reports

Volumn 13, Issue 8, 2013, Pages

  Swan, Matthew ^a   Saunders Pullman, Rachel ^a  

^a BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

Dementia with Lewy bodies; Gaucher disease; GBA; Parkinson disease; Parkinsonism; Glucocerebrosidase

Indexed keywords

6 FLUORODOPA F 18; ALPHA SYNUCLEIN; BETA GLUCOCEREBROSIDASE; FLUORODEOXYGLUCOSE F 18; GLUCOSYLCERAMIDASE; UNCLASSIFIED DRUG;

ANXIETY; APATHY; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; COGNITIVE DEFECT; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME REPLACEMENT; GAIN OF FUNCTION MUTATION; GAUCHER DISEASE; GBA GENE; GENE FUNCTION; GENOTYPE PHENOTYPE CORRELATION; HALLUCINATION; HETEROZYGOSITY; HUMAN; IDIOPATHIC DISEASE; LOSS OF FUNCTION MUTATION; MUTATIONAL ANALYSIS; NEUROIMAGING; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARKINSON DISEASE; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROTEIN FUNCTION; RISK ASSESSMENT; TRANSCRANIAL DOPPLER; ENDOPHENOTYPE; ENZYMOLOGY; GENETIC COUNSELING; GENETIC PREDISPOSITION; GENETICS; MOLECULARLY TARGETED THERAPY; MUTATION; PARKINSONISM; REVIEW;

ALPHA-SYNUCLEIN; ENDOPHENOTYPES; GAUCHER DISEASE; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GLUCOSYLCERAMIDASE; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; NEUROIMAGING; PARKINSONIAN DISORDERS;

EID: 84879369287     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-013-0368-x     Document Type: Article

References (75)

1. Shen L, Yin ZH, Wan Y, et al. Association between ATM polymorphisms and cancer risk: a meta-analysis. Mol Biol Rep. 2012;39:5719-25.
2. Sidransky E. Gaucher disease: complexity in a »simple» disorder. Mol Genet Metab. 2004;83:6-15.
3. Neudorfer O, Giladi N, Elstein D, et al. Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM. 1996;89:691-4.
4. Saunders-Pullman R, Hagenah J, Dhawan V, et al. Gaucher disease ascertained through a Parkinson's center: imaging and clinical characterization. Mov Disord. 2010;25:1364-72.
5. Neumann J, Bras J, Deas E, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain. 2009;132:1783-94.
6. Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med. 2009;361:1651-61.
7. • Lesage S, Anheim M, Condroyer C, et al. Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease. Hum Mol Genet. 2011;20:202-10. This study confirmed an association between GBA mutations and PD in a homogeneous European population, building on prior epidemiological studies, such as that by Sidransky et al. [6]. In this study, the authors evaluated 786 PD patients with familial PD, recruited from 525 unrelated multiplex families, as well as 605 patients with sporadic PD, and 391 controls. Overall, 6.7% of PD patients (including familial and sporadic cases) carried GBA mutations, compared with 1% of controls, conferring an odds ratio of GBA carriage in PD patients of 6.98. Among patients with a family history of PD, 8.4% carried GBA mutations, compared with 5.3% of sporadic PD patients. Comparing the carriage rates with those of other PD-related genes, the authors concluded that GBA may be the commonest genetic risk factor for PD, especially familial PD, in their cohort of European patients. These results robustly reinforce the work of other authors in defining GBA as a potential genetic risk factor for PD.
8. • Alcalay RN, Caccappolo E, Mejia-Santana H, et al. Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology. 2012;78:1434-40. In this study, the investigators sought to define the cognitive profile of GBA-associated PD, building on prior findings of increased risk of cognitive impairment in GBA carriers compared with noncarriers. They used the widely available and easily administered Mini Mental State Examination, as well as a more comprehensive neuropsychological battery. They found that although GBA carriers did not differ from noncarriers in terms of demographics, olfactory function, and motor severity, they had worse performance on multiple cognitive tasks, including the Mini Mental State Examination, and memory and visuospatial tasks. Most prominently, they had significant difficulty in the nonverbal memory domain. These findings underscore the fact that GBA-associated PD carries the risk of general cognitive impairment, with enhanced vulnerability in particular cognitive domains.
9. Choi JH, Stubblefield B, Cookson MR, et al. Aggregation of alpha-synuclein in brain samples from subjects with glucocerebrosidase mutations. Mol Genet Metab. 2011;104:185-8.
10. Gan-Or Z, Giladi N, Rozovski U, et al. Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology. 2008;70:2277-83.
11. Kumar KR, Lohmann K, Klein C. Genetics of Parkinson disease and other movement disorders. Curr Opin Neurol. 2012;25:466-74.
12. Tayebi N, Callahan M, Madike V, et al. Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. Mol Genet Metab. 2001;73:313-21.
13. Tayebi N, Walker J, Stubblefield B, et al. Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol Genet Metab. 2003;79:104-9.
14. Bembi B, Zambito Marsala S, Sidransky E, et al. Gaucher's disease with Parkinson's disease: clinical and pathological aspects. Neurology. 2003;61:99-101.
15. Bultron G, Kacena K, Pearson D, et al. The risk of Parkinson's disease in type 1 Gaucher disease. J Inherit Metab Dis. 2010;33:167-73.
16. Rosenbloom B, Balwani M, Bronstein JM, et al. The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher Registry. Blood Cells Mol Dis. 2011;46:95-102.
17. Wong K, Sidransky E, Verma A, et al. Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab. 2004;82:192-207.
18. Parkkinen L, Neumann J, O'Sullivan SS, et al. Glucocerebrosidase mutations do not cause increased Lewy body pathology in Parkinson's disease. Mol Genet Metab. 2011;103:410-2.
19. Goker-Alpan O, Schiffmann R, LaMarca ME, et al. Parkinsonism among Gaucher disease carriers. J Med Genet. 2004;41:937-40.
20. Lwin A, Orvisky E, Goker-Alpan O, et al. Glucocerebrosidase mutations in subjects with parkinsonism. Mol Genet Metab. 2004;81:70-3.
21. Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med. 2004;351:1972-7.
22. Clark LN, Ross BM, Wang Y, et al. Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology. 2007;69:1270-7.
23. Tan EK, Tong J, Fook-Chong S, et al. Glucocerebrosidase mutations and risk of Parkinson disease in Chinese patients. Arch Neurol. 2007;64:1056-8.
24. Gutti U, Fung HC, Hruska KS, et al. The need for appropriate genotyping strategies for glucocerebrosidase mutations in cohorts with Parkinson disease. Arch Neurol. 2008;65:850-1. author reply 851.
25. Wu YR, Chen CM, Chao CY, et al. Glucocerebrosidase gene mutation is a risk factor for early onset of Parkinson disease among Taiwanese. J Neurol Neurosurg Psychiatry. 2007;78:977-9.
26. De Marco EV, Annesi G, Tarantino P, et al. Glucocerebrosidase gene mutations are associated with Parkinson's disease in southern Italy. Mov Disord. 2008;23:460-3.
27. Kalinderi K, Bostantjopoulou S, Paisan-Ruiz C, et al. Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Greece. Neurosci Lett. 2009;452:87-9.
28. Bras J, Paisan-Ruiz C, Guerreiro R, et al. Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Portugal. Neurobiol Aging. 2009;30:1515-7.
29. Mao XY, Burgunder JM, Zhang ZJ, et al. Association between GBA L444P mutation and sporadic Parkinson's disease from mainland China. Neurosci Lett. 2010;469:256-9.
30. Sun QY, Guo JF, Wang L, et al. Glucocerebrosidase gene L444P mutation is a risk factor for Parkinson's disease in Chinese population. Mov Disord. 2010;25:1005-11.
31. Dos Santos AV, Pestana CP, Diniz KR, et al. Mutational analysis of GIGYF2, ATP13A2 and GBA genes in Brazilian patients with early-onset Parkinson's disease. Neurosci Lett. 2010;485:121-4.
32. Hu FY, Xi J, Guo J, et al. Association of the glucocerebrosidase N370S allele with Parkinson's disease in two separate Chinese Han populations of mainland China. Eur J Neurol. 2010;17:1476-8.
33. Lesage S, Condroyer C, Hecham N, et al. Mutations in the glucocerebrosidase gene confer a risk for Parkinson disease in North Africa. Neurology. 2011;76:301-3.
34. Noreau A, Riviere JB, Diab S, et al. Glucocerebrosidase mutations in a French-Canadian Parkinson's disease cohort. Can J Neurol Sci. 2011;38:772-3.
35. Moraitou M, Hadjigeorgiou G, Monopolis I, et al. β- Glucocerebrosidase gene mutations in two cohorts of Greek patients with sporadic Parkinson's disease. Mol Genet Metab. 2011;104:149-52.
36. Huang CL, Wu-Chou YH, Lai SC, et al. Contribution of glucocerebrosidase mutation in a large cohort of sporadic Parkinson's disease in Taiwan. Eur J Neurol. 2011;18:1227-32.
37. Emelyanov A, Boukina T, Yakimovskii A, et al. Glucocerebrosidase gene mutations are associated with Parkinson's disease in Russia. Mov Disord. 2012;27:158-9.
38. Choi JM, Kim WC, Lyoo CH, et al. Association of mutations in the glucocerebrosidase gene with Parkinson disease in a Korean population. Neurosci Lett. 2012;514:12-5.
39. Guimaraes Bde C, Pereira AC, Rodrigues Fda C, et al. Glucocerebrosidase N370S and L444P mutations as risk factors for Parkinson's disease in Brazilian patients. Parkinsonism Relat Disord. 2012;18:688-9.
40. Aharon-Peretz J, Badarny S, Rosenbaum H, et al. Mutations in the glucocerebrosidase gene and Parkinson disease: phenotype-genotype correlation. Neurology. 2005;65:1460-1.
41. Gan-Or Z, Bar-Shira A, Mirelman A, et al. LRRK2 and GBA mutations differentially affect the initial presentation of Parkinson disease. Neurogenetics. 2010;11:121-5.
42. Nichols WC, Pankratz N, Marek DK, et al. Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology. 2009;72:310-6.
43. Goker-Alpan O, Giasson BI, Eblan MJ, et al. Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology. 2006;67:908-10.
44. Clark LN, Kartsaklis LA, Wolf Gilbert R, et al. Association of glucocerebrosidase mutations with dementia with Lewy bodies. Arch Neurol. 2009;66:578-83.
45. Mata IF, Samii A, Schneer SH, et al. Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders. Arch Neurol. 2008;65:379-82.
46. Alcalay RN, Mejia-Santana H, Tang MX, et al. Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease. J Clin Exp Neuropsychol. 2010;32:775-9.
47. • Brockmann K, Srulijes K, Hauser AK, et al. GBA-associated PD presents with nonmotor characteristics. Neurology. 2011;77:276-80. This study compared 20 PD patients with GBA mutations and 20 IPD patients matched for sex and disease duration, in terms of motor severity and nonmotor symptoms, including cognitive impairment, affective disturbance, olfactory dysfunction, sleep disturbance, and autonomic derangements. Although the two groups did not differ significantly in motor symptoms, the GBA carriers demonstrated a greater burden of cognitive, neuropsychiatric, and autonomic symptoms. These findings reinforce the suspicion that GBA-associated PD presents differently from IPD, and may confer a higher risk of particular nonmotor disturbances.
48. • Seto-Salvia N, Pagonabarraga J, Houlden H, et al. Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson's disease course. Mov Disord. 2012;27:393-9. This study further underscored the cognitive impact of GBA carriage among PD patients. The authors prospectively recruited 225 PD patients, as well as 186 healthy controls. They also assessed 17 brain specimens with a pathological diagnosis of DLB. GBA carriage was highest in the DLB specimens (11.8%), followed by the PD patients (9.8%) and then the controls (0.5%). Among the PD patients and the controls, the diagnosis of dementia was defined according to the Clinical Dementia Rating scale and DSM-IV criteria. Of GBA carriers, 50% had a diagnosis of dementia, compared with 24% of noncarriers. These findings underscore the fact that GBA mutations may be common in DLB, and that GBA-associated PD carries a greater risk of dementia than non-GBA-associated PD.
49. Goker-Alpan O, Lopez G, Vithayathil J, et al. The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations. Arch Neurol. 2008;65:1353-7.
50. Barrett MJ, Shanker VL, Severt WL, et al. Cognitive outcomes in glucocerebrosidase mutation associated Parkison disease. Neurology. 2013;80:S13.005.
51. Walter U, Skoloudik D, Berg D. Transcranial sonography findings related to non-motor features of Parkinson's disease. J Neurol Sci. 2010;289:123-7.
52. Barrett MJ, Hagenah J, Dhawan V, et al. Transcranial sonography and functional imaging in glucocerebrosidase mutation Parkinson disease. Parkinsonism Relat Disord. 2013;19:186-91.
53. Kresojevic N, Mijajlovic M, Peric S, et al. Transcranial sonography in patients with Parkinson's disease with glucocerebrosidase mutations. Parkinsonism Relat Disord. 2013;19:431-5.
54. Kono S, Shirakawa K, Ouchi Y, et al. Dopaminergic neuronal dysfunction associated with parkinsonism in both a Gaucher disease patient and a carrier. J Neurol Sci. 2007;252:181-4.
55. Kono S, Ouchi Y, Terada T, et al. Functional brain imaging in glucocerebrosidase mutation carriers with and without parkinsonism. Mov Disord. 2010;25:1823-9.
56. Kraoua I, Stirnemann J, Ribeiro MJ, et al. Parkinsonism in Gaucher's disease type 1: ten new cases and a review of the literature. Mov Disord. 2009;24:1524-30.
57. Goker-Alpan O, Masdeu JC, Kohn PD, et al. The neurobiology of glucocerebrosidase-associated parkinsonism: a positron emission tomography study of dopamine synthesis and regional cerebral blood flow. Brain. 2012;135:2440-8.
58. Barrett MJ, Giraldo P, Capablo JL, et al. Greater risk of parkinsonism associated with non-N370S GBA1 mutations. J Inherit Metab Dis. 2013;36:575-80.
59. • Westbroek W, Gustafson AM, Sidransky E. Exploring the link between glucocerebrosidase mutations and parkinsonism. Trends Mol Med. 2011;17:485-93. In this review, the authors explore multiple proposed mechanisms of PD pathogenesis, and the extent to which evidence implicates GBA mutations in each of them. Specifically, they evaluate α-synuclein aggregation, lysosomal pathways, cellular autophagy, mitochondrial dysfunction, dysfunctional ERAD of proteins, altered lipid metabolism, and the prion-protein hypothesis. They do not find a role for mitochondrial dysfunction or the prion-protein hypothesis in GBA-associated PD, but for the others they discuss evidence either clearly linking GBA mutations to the respective mechanism or persuasively connecting them to known pathophysiological pathways.
60. •• Mazzulli JR, Xu YH, Sun Y, et al. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell. 2011;146:37-52. This pivotal work used induced pluripotent stem cells to expand the model for the relationship between enzyme and α-syncluclein aggregation in GBA-associated PD, and suggests a model whereby there may be a role for ß-glucocerebrosidase modification in the treatment of IPD as well.
61. • Gegg ME, Burke D, Heales SJ, et al. Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann Neurol. 2012;72:455-63. The authors demonstrate that ß-glucocerebrosidase activity is decreased in substantia nigra of brains with GBA mutations, but it is also diminished in those with IPD without GBA mutations, paving the way for possible application of therapies that modulate ß-glucocerebrosidase to IPD as well.
62. Balducci C, Pierguidi L, Persichetti E, et al. Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson's disease. Mov Disord. 2007;22:1481-4.
63. Yap TL, Gruschus JM, Velayati A, et al. Alpha-synuclein interacts with glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases. J Biol Chem. 2011;286:28080-8.
64. • Cullen V, Sardi SP, Ng J, et al. Acid beta-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter alpha-synuclein processing. Ann Neurol. 2011;69:940-53. Together with that of Mazzulli et al. [60], this study expands our understanding of the relationship between ß-glucocerebrosidase and α-synuclein processing.
65. Goker-Alpan O, Stubblefield BK, Giasson BI, et al. Glucocerebrosidase is present in alpha-synuclein inclusions in Lewy body disorders. Acta Neuropathol. 2010;120:641-9.
66. Ron I, Rapaport D, Horowitz M. Interaction between parkin and mutant glucocerebrosidase variants: a possible link between Parkinson disease and Gaucher disease. Hum Mol Genet. 2010;19:3771-81.
67. Brockmann K, Hilker R, Pilatus U, et al. GBA-associated PD. Neurodegeneration, altered membrane metabolism, and lack of energy failure. Neurology. 2012;79:213-20.
68. Schmid SP, Schleicher ED, Cegan A, et al. Cerebrospinal fluid fatty acids in glucocerebrosidase-associated Parkinson's disease. Mov Disord. 2012;27:288-92.
69. Sobstyl M, Zabek M, Koziara H, et al. A patient with parkinsonism related to Gaucher's disease type I successfully treated by unilateral pallidotomy - a 3-year follow-up. Neurol Neurochir Pol. 2009;43:293-7.
70. Hughes DA, Ginsberg L, Baker R, et al. Effective treatment of an elderly patient with Gaucher's disease and Parkinsonism: a case report of 24 months' oral substrate reduction therapy with miglustat. Parkinsonism Relat Disord. 2007;13:365-8.
71. Goker-Alpan O, Sidransky E. Treating patients with Gaucher disease and parkinsonism: misrepresentation in a title. Parkinsonism Relat Disord. 2008;14:81-2. author reply 83.
72. Sardi SP, Clarke J, Viel C, et al. Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies. Proc Natl Acad Sci USA. 2013;110:3537-42.
73. Schapira AH, Gegg ME. Glucocerebrosidase in the pathogenesis and treatment of Parkinson disease. Proc Natl Acad Sci USA. 2013;110:3214-5.
74. • Anheim M, Elbaz A, Lesage S, et al. Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers. Neurology. 2012;78:417-20. Although earlier epidemiological studies established GBA carriage as a risk factor for PD, the risk of developing PD for an individual carrier has remained relatively undefined; thus, genetic counseling for family members of GBA carriers with PD has remained challenging. In this study, the authors reviewed the pedigrees of 525 probands with familial PD, and screened a large number of family members, including those with and those without PD, for GBA mutations. Using this data, and using a model that assumes GBA is an autosomal dominant PD gene with incomplete penetrance, the authors calculated an age-related penetrance of PD in GBA carriers of 7.6% at age 50 years, 13.7% at age 60 years, 21.4% at age 70 years, and 29.7% at age 80 years. Although some concerns have been raised about the study's methodology and assumptions (see [75]), this study provides an important starting point for gathering information that will guide genetic testing and counseling in families with PD related to GBA mutations.
75. Sidransky E, Hart PS. Penetrance of PD in glucocerebrosidase gene mutation carriers. Neurology. 2012;79:106-7.